{"id":788228,"date":"2026-10-01T05:58:10","date_gmt":"2026-10-01T05:58:10","guid":{"rendered":"https:\/\/www.newsbeep.com\/uk\/788228\/"},"modified":"2026-10-01T05:58:10","modified_gmt":"2026-10-01T05:58:10","slug":"experimental-therapy-k-9-restores-lost-vision-mobility-in-ms-mice","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/uk\/788228\/","title":{"rendered":"Experimental therapy K-9 restores lost vision, mobility in MS mice"},"content":{"rendered":"<p>An experimental therapy called kamuvudine-9 (K-9) reversed established paralysis and vision loss in a mouse model of <a href=\"https:\/\/multiplesclerosisnewstoday.com\/multiple-sclerosis-overview\/\" rel=\"nofollow noopener\" target=\"_blank\">multiple sclerosis<\/a> (MS), offering hope for treatments that can restore lost function rather than just prevent future damage.<\/p>\n<p>\u201cMost <a href=\"https:\/\/multiplesclerosisnewstoday.com\/approved-treatments-for-multiple-sclerosis\/\" rel=\"nofollow noopener\" target=\"_blank\">MS therapies<\/a> are aimed at preventing the next attack. What\u2019s remarkable is that K-9 not only prevented further neurological deterioration, but animals recovered function they had already lost,\u201d Jayakrishna Ambati, MD, co-author of the study at the University of Virginia, said in a <a href=\"https:\/\/www.eurekalert.org\/news-releases\/1144864\" rel=\"nofollow noopener\" target=\"_blank\">university news story<\/a>.<\/p>\n<p>The therapy was derived from a common class of antiviral medications known as nucleoside reverse transcriptase inhibitors (NRTIs). Beyond the animal findings, real-world insurance data showed that people taking these antivirals had lower rates of MS and fewer disease flare-ups.<\/p>\n<p>  Recommended Reading<\/p>\n<p>        <img decoding=\"async\" src=\"https:\/\/www.newsbeep.com\/uk\/wp-content\/uploads\/2026\/10\/IMG_1873-150x0-c-default.png\" alt=\"\"\/><\/p>\n<p>Experimental therapy shows dual protection<\/p>\n<p>\u201cThese findings provide a rationale for further investigating K-9 for treating MS,\u201d researchers wrote in the study \u201c<a href=\"https:\/\/www.science.org\/doi\/10.1126\/scitranslmed.aei2870\" rel=\"nofollow noopener\" target=\"_blank\">The nucleoside analog kamuvudine-9 shows protective and therapeutic efficacy in a mouse model of multiple sclerosis<\/a>,\u201d which was published in Science Translational Medicine. The work was funded by the National Institutes of Health (NIH).<\/p>\n<p>\u201cThe remarkable reversal of some of MS\u2019s most severe complications in animals, taken together with this drug\u2019s promising safety profile, present a very compelling translational pathway,\u201d Michael F. Chiang, MD, director of NIH\u2019s National Eye Institute, said in a <a href=\"https:\/\/www.nih.gov\/news-events\/news-releases\/modified-hiv-drug-reverses-vision-loss-paralysis-multiple-sclerosis-model\" rel=\"nofollow noopener\" target=\"_blank\">press release<\/a>.<\/p>\n<p>MS is an inflammatory disease that causes damage to the nervous system. A complex of inflammatory molecules known as the inflammasome has been implicated in the progression of MS. Normally, the inflammasome acts as a molecular alarm system, detecting infectious invaders and rallying the immune system to attack them. However, in MS, the inflammasome may become chronically activated, leading to prolonged inflammation that drives disease processes.<\/p>\n<p>NRTIs are a class of antiviral medications used to treat HIV and hepatitis B. These medications block the replication of these viruses, but they have also been found to inhibit the inflammasome, and in a recent study, <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10158986\/\" rel=\"nofollow noopener\" target=\"_blank\">NRTIs preserved vision<\/a> in a mouse model of eye damage. Because vision loss is also a common problem in MS and the inflammasome is implicated in the disease, researchers hypothesized that NRTI treatment may offer benefits in MS.<\/p>\n<p>K-9 was derived from NRTIs by essentially removing the parts of the medication that have antiviral effects, while preserving the inflammasome-inhibiting components. The goal was to minimize neurological and muscular side effects that are associated with NRTIs, making the therapy safer.<\/p>\n<p>The researchers tested K-9 in mice with experimental autoimmune encephalitis, a lab-induced immune disorder used to model MS. The treatment reversed paralysis and vision loss while preserving <a href=\"https:\/\/multiplesclerosisnewstoday.com\/myelin-sheath\/\" rel=\"nofollow noopener\" target=\"_blank\">myelin<\/a>, the fatty covering around nerves that is damaged in MS, as well as nerve fibers in the brain and spinal cord. K-9 also reduced levels of neurofilament light chain (NfL), a marker of nerve damage that indicates disease activity in MS.<\/p>\n<p>Real-world data supports human trials<\/p>\n<p>The researchers then analyzed MS rates in three groups of human patients taking NRTIs: those taking these medications to manage HIV or hepatitis B infection, or those taking NRTIs as preexposure prophylaxis to reduce the risk of contracting HIV. In all three groups, the use of NRTIs was associated with lower MS risk. In a cohort of MS patients, individuals taking NRTIs tended to have fewer disease <a href=\"https:\/\/multiplesclerosisnewstoday.com\/ms-flares\/\" rel=\"nofollow noopener\" target=\"_blank\">flares<\/a>.<\/p>\n<p>\u201cThough NRTIs are different molecules, they too block inflammasome activation and the signal we detected here is exactly what we would expect to see if K-9 does one day prove effective in humans,\u201d Ambati said.<\/p>\n<p>Collectively, these data support K-9 or other NRTI derivatives as <a href=\"https:\/\/multiplesclerosisnewstoday.com\/experimental-treatments-for-multiple-sclerosis\/\" rel=\"nofollow noopener\" target=\"_blank\">potential MS treatments<\/a>. The researchers called for further research examining this medication class in MS.<\/p>\n<p>\u201cWhen [the reversal of paralysis and vision loss in animal models] is considered together with the preservation of nerve tissue, the NfL response and the human epidemiologic findings, we believe there is a compelling rationale to test this approach in patients,\u201d Ambati said.<\/p>\n","protected":false},"excerpt":{"rendered":"An experimental therapy called kamuvudine-9 (K-9) reversed established paralysis and vision loss in a mouse model of multiple&hellip;\n","protected":false},"author":2,"featured_media":788229,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[59,102,56,54,55],"class_list":["post-788228","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-gb","tag-health","tag-uk","tag-united-kingdom","tag-unitedkingdom"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/788228","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/comments?post=788228"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/posts\/788228\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media\/788229"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/media?parent=788228"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/categories?post=788228"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/uk\/wp-json\/wp\/v2\/tags?post=788228"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}